Who would be a poor man, a beggarman, a thief --
if he had a rich man in his hand.
And who would steal the candy
from a laughing baby's mouth
if he could take it from the money man.
Cross-eyed Mary goes jumping in again.
She signs no contract
but she always plays the game.
Dines in Hampstead village
on expense accounted gruel,
and the jack-knife barber drops her off at school.
Laughing in the playground -- gets no kicks from little boys:
would rather make it with a letching grey.
Or maybe her attention is drawn by Aqualung,
who watches through the railings as they play.
Cross-eyed Mary finds it hard to get along.
She's a poor man's rich girl
and she'll do it for a song.
She's a rich man stealer
but her favour's good and strong:
She's the Robin Hood of Highgate --
helps the poor man get along.
In recent years, with the rapid development of the Internet video industry in mainland China, a series of copyright disputes and lawsuits have arisen. During the rights safeguarding process, Youku Tudou Inc. insisted on protecting its own interests with legal representation. Even though it paid considerable costs in safeguarding their rights and interests, the significance and meaning of success was much greater than the compensation obtained from Youku Tudou Inc.. Chinese government and judicial departments' tolerance for copyright infringement in grey zones is getting lower and lower, and reflects their strong determination to protect intellectual property rights. T
Prana Biotechnology (NASDAQ:PRAN; ASX:PBT)
it has received a A$2.
refund under the R&D Tax Incentive
Program, a program administered by
d the Australian T
payment is part of approximately $5.8 mil
ion expected to be received for the 2011
13 financial years
clinical development of PBT2 for
Alzheimer’s diseases, as well as other
Parkinson’s disease and other neurological indications
his Australian Government funded program is commendable because it provides
significant amounts of non
dilutive cash to suppor
addition to the $2.
million just received, we
of over A$3
million for R&D activities
from 1 July 2012 to 30 June
Geoffrey Kempler, Prana’s Chairman
Journal of Huntington’s Disease 1 (2012) 211–219
PBT2 Reduces Toxicity in a C. elegans
Model of polyQ Aggregation and Extends
Lifespan, Reduces Striatal Atrophy and
Improves Motor Performance in the R6/2
Mouse Model of Huntington’s Disease
Robert A. Cherny, Scott Aytona , David I. Finkelstein, Ashley I. Bush, Gawain McColl
and Stephen M. Massa
Background: There is evidence that interaction with biologically important metals, particularly copper and iron, contributes to the pathological aggregation and toxicity of the mutant huntingtin protein in HD. PBT2 is a novel 8-hydroxyquinoline drug in clinical trials for AD and HD which restores metal homeostasis and has demonstrated neuroprotective and cognitive beneﬁts in animal models of AD and in a Phase IIa clinical trial in AD patients.
Objectives: We assessed efﬁcacy of PBT2 to improve function in nematode and mouse models of HD.
Methods: We assessed the effects of PBT2 on motility in a strain of C. elegans engineered to overexpress an extended polyg-lutamine tract. We then assessed the effects of daily oral administration of PBT2 on the R6/2 mouse a vertebrate model of HD. Behavioural measures (Rotarod performance, clasping latency and duration) and measures of overall health (body weight,
lifespan) were assessed throughout the study. At conclusion brains were evaluated for weight and lateral ventricle area.
Results: PBT2 signiﬁcantly decreased paralysis caused by overexpression of an extended polyglutamine tract in a C. elegans. R6/2 mice treated with PBT2 showed signiﬁcantly better performance in the Rotarod task and signiﬁcantly decreased duration of clasping than control animals. Mean body weight and brain weight in the PBT2 treatment group were signiﬁcantly higher
than the control cohort and median lifespan was prolonged by 26%. Mean lateral ventricle area in the PBT2-treated group was 46% smaller than in the control group.
Conclusions: Treatment with PBT2 may be beneﬁcial as a disease modifying therapy for HD.
Keywords: PBT2, C. elegans, R6/2, metals
∗ Correspondence to: Robert Cherny PhD, The Mental Health
Research Institute, The University of Melbourne, Royal Pde,
Parkville, VIC, Australia. Tel.: +61 3 90356714; E-mail: rcherny@
SSN 1879-6397/12/$27.50 © 2012 – IOS Press and the authors. All rights reserved
This article is published online with Open Access and distributed under the terms of the Creative Commons Attribution Non-Commercial
The Aussies seem to like the stock more than the Nasdac-ies. Makes you wonder. I wonder if some people know the drug is working.